part

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Results fromthe primary analysis of a randomized, controlled, open-label, Phase3 study showed that 77 percent of treatment-experienced HIV-1infected adults taking PREZISTA(TM) (darunavir) 600 mg tablets with100 mg ritonavir (PREZISTA/r) twice daily, plus an optimizedbackground regimen (OBR) of antiretroviral (ARV) agents, reached aplasma v...

GenoLogics Announces Bioinformatics Partnership with Illumina

GenoLogics Announces Bioinformatics Partnership withIllumina BEYOND GENOME CONFERENCE, San Francisco, CA, June 21, 2007-GenoLogics, a leading developer of lab and data managementsoftware solutions for life sciences research, today announced thatit has penned an agreement with Illumina, Inc. to become atechnology partner and participant in IlluminaConnect, abioinformatics software...

Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - NovelosTherapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical companyfocused on the development of therapeutics to treat cancer andhepatitis, today announced encouraging results in an ongoingDana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002in combination with carboplatin in platinum-resistant ovariancancer patients. To date, 10...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles

CLEVELAND--(BUSINESS WIRE)--Jun 4, 2007 - Copernicus Therapeutics,Inc. announced today that a research team at University of OklahomaHealth Sciences Center, led by Dr. Muna Naash, Professor of CellBiology, demonstrated that Copernicus' DNA nanoparticles correctedvision defects in a mouse model of retinitis pigmentosa (RP). Thesefindings were presented at the American Society of Gene Therapy...

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably withthe activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partner,Keryx Biopharmaceuticals presented a poster outlining Phase 1 andPhase 2 results for perifosine, an oral...

In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression

SAN DIEGO, California, 23 May 2007 - The antidepressant duloxetinehydrochloride was equally effective in reducing painful symptoms indepressed patients who did not respond, or responded onlypartially, to treatment with a selective serotonin reuptakeinhibitor (SSRI), regardless of whether those patients wereswitched from an SSRI abruptly or gradually. This newdata was presented t...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partnerSpectrum Pharmaceuticals presented an abstract outlining detailedPhase 2 results for AEterna Zentaris' fourth-generation luteinizinghormone-r...

Inovio Biomedical's Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--May 17, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-basedvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat partners of the company will present new interim data from twophase I clinical trials of plasmid-based immunotherapies usingInovio's electropor...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCytePharmaceuticals presented preclinical data today showing thatimmunization with their influenza virus-like particles (VLPs)induced heterosubtypic protection in a virus challenge study. Thecompany's data were presented by Dr. Joel Haynes, LigoCyte's seniordirector of vaccine development, at the Tenth Annual Conference onVaccine Research...

New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures

Data Presented at the American Academy of Neurology Annual MeetingShow Approximately 50 Percent Reduction in Partial Seizures BOSTON, May 01, 2007 /PRNewswire/ -- Data from two clinicaltrials presented today at the American Academy of Neurology (AAN)meeting suggest that an investigational once daily extended releaseformulation of Lamictal(R) (lamotrigine) is effective as add-ontreatment i...

Evidence of Nanoparticles Found in Plaque-Filled Arteries

ROCHESTER, Minn., April 30. 2007-- Scientific evidenceincreasingly links arterial calcification to the presence ofnanosized particles -- so small that some scientists questionwhether a nanoparticle can live and, if so, play a viable role incausing disease. A new Mayo Clinic study cites evidence showing the presence ofnanoparticles near plaque-filled arteries in animal models....

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation(NASDAQ:CYTR) today announced that the RNA interference (RNAi)delivery technology exclusively licensed to its majority-ownedsubsidiary, RXi Pharmaceuticals Corporation (RXi), has beenpublished in the April 2007 issue of peer-reviewed scientificjournal ACS Chemical Biology. The technology was developed by RXiCo-founder, Scientific...

UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age

UCB Announces Positive Top-Line Phase III Results forKeppra® as Adjunctive Therapy for Partial Onset Seizures inPaediatric Patients from One Month to Less than Four Years ofAge BRUSSELS, Belgium - April 20, 2007 - UCB today announcedpositive top-line results from a phase III, double-blind,randomized, multi-centre, placebo-controlled study evaluating theefficacy and tolerabilit...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, announced results from two pre-clinical studies thatsupport the role of SPARC (secreted protein acidic and rich incysteine) expression in cancer and Abraxis' nanoparticlealbumin-bound (nab(TM)) tumor-targeting technology at the 98thAmerican Association for Canc...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...

Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals announces that results from three Phase 2 studiesof ISIS 301012, including effects of ISIS 301012 in homozygousfamilial hypercholesterolemic (HoFH) patients, will be the subjectsof three upcoming presentations at the of Cardiology (ACC), March24-27 in New Orleans. Planned presentations include effects of ISIS3...

Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-EdenPharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it wasinformed late Wednesday, March 07, 2007, by the Department ofHealth & Human Services (HHS) that NEUMUNE(R), the Company'sproduct candidate for the treatment of Acute Radiation Syndrome(ARS) was found technically unacceptable and was no longer in thecompetitive range for th...